Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Cash Taxes 3 year CAGR for the year ending December 31, 2022

Freeline Therapeutics Holdings Plc Cash Taxes 3 year CAGR is NA for the year ending December 31, 2022. Cash taxes represent the total amount of cash paid for income taxes, including both current and deferred taxes. It is calculated by summing the income tax provision and any non-cash tax-related items. This metric provides insight into the company's cash outflows related to taxes, which can impact its overall cash position and liquidity. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Freeline Therapeutics Holdings Plc Cash Taxes for the year ending December 31, 2022 was USD -4.61 M, a -1,041.43% change year over year.
  • Freeline Therapeutics Holdings Plc Cash Taxes for the year ending December 31, 2021 was USD 490.00 K, a 139.02% change year over year.
  • Freeline Therapeutics Holdings Plc Cash Taxes for the year ending December 31, 2020 was USD 205.00 K.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email